In the first of the Tech Talk series, Novarum founder and BBI group head of mobile, Dr Neil Polwart, goes through his seven key tips that should be kept at front of mind when trying to implement a successful mHealth strategy.
The World Health Organisation (WHO) has released its first set of surveillance data on antibiotic resistance, revealing high levels of resistance to several serious bacterial infections globally.
As we embark on a difficult flu season, I look at why infection rates vary so much year on year and the potential universal vaccine one company is progressing through the clinical development stages.
The latest report from data and analytics company, GlobalData, has revealed that the glaucoma market is expected to grow to $3.8 billion in 2026 as a result of the launch of pipeline products.
Administration of quadrivalent flu jabs should be on the agenda for the NHS as fourth flu strain, known as ‘Japanese flu’ is becoming most prevalent in Europe, according to data and analytics company, GlobalData.
Accord Healthcare, a generic pharmaceutical company, has opened a new facility in Fawdon, Newcastle, expanding its portfolio to four sites situated within the UK.
Spotting the signs and symptoms of various infectious diseases can mean the difference between life and death. According to research in the journal Epidemiology and Infection, public awareness campaigns are vital in stopping infections spreading
The Brexit Health Alliance (BHA) has urged for regulatory arrangements to be made as a matter of urgency to prevent any potential risk to public health as a result of Brexit.
Global innovator and provider of cold chain packaging systems for the pharma industry, Softbox, has acquired TP3 Global, which manufactures the ‘SilverSkin’ brand.
A new report released by the BioIndustry Association (BIA) and Informa Pharma Intelligence has revealed that the UK has the strongest research and development (R&D) pipeline in Europe.
The Access to Medicine Foundation has published an independent analysis of the efforts made by pharma companies to address the issue of drug resistant infections.
